CryoLife Inc (NYSE: CRY), a cardiac and vascular surgery company focused on aortic disease, announced on Wednesday that it has received the CE Mark for the E-vita Open NEO, a hybrid stent graft system intended for the treatment of aortic arch disease.

The company says that its hybrid stent graft technologies that include the E-vita Open NEO and the E-vita Open Plus, allow a one-stage procedure treatment of this condition by integrating the surgical arch repair and the endovascular descending thoracic repair, offering a more cost effective solution for the health system and allowing the patient to avoid a second surgery. It is expected that E-vita Open NEO will often be utilised in combination with JOTEC's thoracic stent graft offering, E-nya.

Pat Mackin, CryoLife chairman, president, and chief executive officer, said, 'We are pleased to have received CE Mark for E-vita Open NEO, our newest hybrid stent graft technology for aortic arch and descending thoracic aorta repair. This new design features a single tri-branched vessel that enhances ease-of-use and implantation that reduces surgical time and allows for a potentially safer procedure, thereby increasing the likelihood that more patients can benefit from the procedure and patient access to these therapies.'